Abstract 389P
Background
Patients with head and neck cancers often require multimodality treatments. Therefore, cross-resistance to various treatments that are employed for these patients poses a significant therapeutic problem. A better understanding of therapeutic cross-resistance could lead to methods which will circumvent cross-resistance. Herein, we explore erlotinib (anti-EGFr, TKI) and radiation sensitivity in human head and neck cancer cells with acquired resistance to cetuximab (anti-EGFr mAb).
Methods
Two human head and neck squamous cell cancers were utilized for these for these studies; UM-SCC-1 and UM-SCC-6. It has been previously reported that UM-SCC-1 is substantially more radioresistant than UM-SCC-6 (IJROBP 29 (2):243-247,1994). We have previously reported on cell lines that were created by continuous exposure of the above cell lines to 5 μg/ml cetuximab (Biochem Biophys Res Common 517(1): 36-42, 2019 and PLoS ONE 15(2) eo229077,1-14, 2020). Therefore, two cetuximab-resistant cell lines were created; UM-SCC-1R and UM-SCC-6R. Radiation sensitivity and erlotinib sensitivity were investigated through the use of standard proliferation assays and apoptosis assays as previously described (BMC Cancer 15:673, 2015).
Results
For the assessments of radiation sensitivity and erlotinib sensitivity, comparisons were made between the two cetuximab-resistant cell lines (UM-SCC-1R and UM-SCC-6R) with their respective parental cell lines (UM-SCC-1 and UM-SCC-6). It was discovered that the two cetuximab resistant cell lines were also radioresistant relative to their respective parental lines, regarding cell proliferation and apoptosis. However, the two cetuximab resistant cell lines were not cross-resistant to erlotinib.
Conclusions
Acquired resistance to cetuximab was found to correlate with radiation-resistance but not erlotinib-resistance. Since cetuximab is an anti-EGFr monoclonal antibody and erlotinib is an anti-EGFr tyrosine kinase inhibitor, further studies are underway to investigate the role of downstream signaling events that may contribute to our understanding for the lack of cross-resistance between cetuximab and erlotinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. A. Bonner.
Funding
Has not received any funding.
Disclosure
J.A. Bonner: Financial Interests, Personal, Advisory Board: Merck Serono. All other authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract